Abarelix
Alternative Names: Abarelix-depot-F; Abarelix-depot-M; Abarelix-L; Beta-abarelix; Plenaxis; PPI 149; R 3827; β-abarelixLatest Information Update: 22 Jan 2018
At a glance
- Originator Indiana University
- Developer Contura
- Class Antineoplastics; Oligopeptides
- Mechanism of Action LHRH receptor antagonists; Testosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Discontinued Endometriosis
Most Recent Events
- 19 Jan 2018 Speciality European Pharma rebrands itself as Contura
- 21 Sep 2017 Launched for Prostate cancer in Luxembourg and Belgium (IM) before September 2017 (Speciality European Pharma website, September 2017)
- 27 Feb 2015 Launched for Prostate cancer in Denmark and Netherlands (IM) prior to February 2015